-Ethnic and geographic differentiation of Helicobacter pylori within Iran.

Latifi-Navid S, Ghorashi SA, Siavoshi F, Linz B, Massarrat S, Khegay T, Salmanian AH, Shayesteh AA, Masoodi M, Ghanadi K, Ganji A, Suerbaum S, Achtman M, Malekzadeh R, Falush D.

PLoS One. 2010 Mar 22;5(3):e9645.

- Production of polyclonal antibody against alkyl hydroperoxide reductase of Helicobacter pylori and its antigenicity.

 Mohammadian T, Doosti M, Paknejad M, Siavoshi F, Massarrat S, Soukhtanloo M.

Hybridoma (Larchmt). 2008 Dec;27(6):481-5.

- H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria.

 Ashktorab H, Dashwood RH, Dashwood MM, Zaidi SI, Hewitt SM, Green WR, Lee EL, Daremipouran M, Nouraie M, Malekzadeh R, Smoot DT.

Helicobacter. 2008 Dec;13(6):506-17.

- Yeast of the oral cavity is the reservoir of Heliobacter pylori.

 Salmanian AH, Siavoshi F, Akbari F, Afshari A, Malekzadeh R.

J Oral Pathol Med. 2008 Jul;37(6):324-8. Epub 2008 Feb 5.

Sotoudeh M, Derakhshan MH, Abedi-Ardakani B, Nouraie M, Yazdanbod A, Tavangar SM, Mikaeli J, Merat S, Malekzadeh R.

Dig Dis Sci. 2008 Jan;53(1):27-33. Epub 2007 May 10.

-Synthesis and anti-Helicobacter pylori activity of 5-(nitroaryl)-1,3,4-thiadiazoles with certain sulfur containing alkyl side chain.

Foroumadi A, Rineh A, Emami S, Siavoshi F, Massarrat S, Safari F, Rajabalian S, Falahati M, Lotfali E, Shafiee A.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3315-20.Epub2008Apr 15

-Advantage of using a home-made elisa kit for detection of Helicobacter pylori infection over commercially imported kits.

Mohammadi M, Talebkhan Y, Khalili G, Mahboudi F, Massarrat S, Zamaninia L, Oghalaei A.

Indian J Med Microbiol. 2008 Apr-Jun;266(2):127-31

-Antimicrobial effectiveness of ketoconazole against metronidazole-resistant Helicobacter pylori isolates from Iranian dyspeptic patients.

Latifi-Navid S,Siavoshi F,Safari F,Malekzadeh R,Massarrat.S.

J Antimicrob Chemother. 2007 Jan;59(1):160-1. Epub 2006 Nov 3. No abstract available

-Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease.

Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, Vahedi H, Zendehdel N, Sotoudehmanesh R, Agah S, Mikaeli J, Pourshams A, Ali-Asgari A, Malekzadeh R, Massarrat S.

Arch Iran Med. 2007 Apr;10(2):161-7.

- Antimicrobial effectiveness of ketoconazole against metronidazole-resistant Helicobacter pylori isolates from Iranian dyspeptic patients.
Latifi-Navid S, Siavoshi F, Safari F, Malekzadeh R, Massarrat S.
J Antimicrob Chemother. 2006 Nov 3; [Epub ahead of print] No abstract available.

-Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of Helicobacter pylori.
Safaralizadeh R, Siavoshi F, Malekzadeh R, Akbari MR, Derakhshan MH, Sohrabi MR, Massarrat S.
East Mediterr Health J. 2006 May-Jul; 12(3-4):286-93.

- Helicobacter pylori endemic and gastric disease.
Siavoshi F, Malekzadeh R, Daneshmand M, Ashktorab H.
Dig Dis Sci. 2005 Nov; 50(11):2075-80.

-Detection of Helicobacter pylori-specific genes in the oral yeast.
Siavoshi F, Salmanian AH, Akbari F, Malekzadeh R, Massarrat S.
Helicobacter. 2005 Aug; 10(4):318-22. Erratum in: Helicobacter. 2005 Oct; 10(5):557.

-Helicobacter pylori reinfection rate 3 years after successful eradication.
Zendehdel N, Nasseri-Moghaddam S, Malekzadeh R, Massarrat S, Sotoudeh M, Siavoshi F.
J Gastroenterol Hepatol. 2005 Mar; 20(3):401-4.

-Association between Helicobacter pylori Infection in gastric cancer, ulcers and gastritis in Iranian patients.
Siavoshi F, Malekzadeh R, Daneshmand M, Smoot DT,Ashktorab H.
Helicobacter. 2004 Oct; 9(5):470. No abstract available.

-DNA Fingerprinting of H. Pylori Isolates from Iranian Patients by REP-PCR.
Siavoshi F, Zabihinia S, Malekzadeh R, Dinparast Jadid N, Massarrat S, Omrani A.
Govaresh journal, Volume 9, Number 2, Summer 2004, 81-89.

-Neutralization of Helicobacter Pylori Cytotoxicity on Vero Cells by Omeprazole.
Latifi Navid S, Siavoshi F, Mokhtari Azad T, Malekzadeh R, Sohrabi MR, Massarrat S.
Govaresh journal, Volume 9, Number 3, Autumn 2004, 161-168.

-Genotype Variation in H. Pylori Isolates from Iranian Patients by RAPD-PCR.
Siavoshi F, Shokouhfard M, Malekzadeh R, Dinparast Jadid N, Massarrat S, Emrani A.
Govaresh journal, Vol. 9 \ No. 1 \ Spring 2004, 18-21

-Treatment of Helicobacter pylori Infection in Iran: Low Efficacy of Recommended Western Regimens.

 R. Malekzadeh, M. Mohamadnejad, F. Siavoshi, S. Massarrat
Arch Iran Med 2004, Volume 7, Number 1.

-Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.
Fakheri H, Merat S, Hosseini V, Malekzadeh R.
Aliment Pharmacol Ther. 2004 Jan 1; 19(1):89-93.

-Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population.
Malekzadeh R, Merat S, Derakhshan MH, Siavoshi F, Yazdanbod A, Mikaeli J, Sotoudemanesh R, Sotoudeh M, Farahvash MJ, Nasseri-Moghaddam S, Pourshams A, Dolatshahi S, Abedi B, Babaei M, Arshi S, Majidpour A.
J Gastroenterol Hepatol. 2003 Jan; 18(1):13-7.

-Effect of Helicobacter pylori eradication or of ranitidine plus metoclopramide on Helicobacter pylori-positive functional dyspepsia. A randomized, controlled follow-up study.
Alizadeh-Naeeni M, Saberi-Firoozi M, Pourkhajeh A, Taheri H, Malekzadeh R, Derakhshan MH, Massarrat S; Iranian Functional Dyspepsia Study Group.
Digestion. 2002; 66(2):92-8.

-Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial.
Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, Massarrat S.
Eur J Gastroenterol Hepatol. 2001 Aug; 13(8):915-9.

-Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, Massarrat S.
Aliment Pharmacol Ther. 2001 Mar; 15(3):411-6.

-A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
Sotudehmanesh R, Malekzadeh R, Fazel A, Massarrat S, Ziad-Alizadeh B, Eshraghian MR.
J Gastroenterol Hepatol. 2001 Mar; 16(3):264-8.

-Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S.
Digestion. 2001; 64(4):222-5.

 R. Malekzadeh
Arch Irn Med 2001; 4 (4): 212-213

-Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease.
Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari M, Massarrat S.
Aliment Pharmacol Ther. 2000 Mar; 14(3):299-303.

-Susceptibility of Various Strains of Helicobacter pylori to Selected Agents.

F.Siavoshi PhD,A.H.Pourkhajeh MD,S.Merat MD, H.Asl-Soleimani MD, E. Heydarian,M.Khatibian MD,R.Malekzadeh MD.
Arch Irn Med Apr. 2000, Volume 3, Number 2

-Prevalence of Helicobacter Pylori in Two Iranian Provinces with High and Low Incidence of Gastric Carcinoma.

J. Mikaeli MD, R. Malekzadeh MD, B. Ziad Alizadeh MD, S. Nasseri Mogaddam MD, M.Valizadeh MD, R. Khoncheh MD,S.Massarrat MD.
Arch Irn Med Jan. 2000, Volume 3, Number 1

-Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin.
Kashifard M, Malekzadeh R, Siavoshi F, Mikaeli J, Massarrat S.
Eur J Gastroenterol Hepatol. 1998 Oct; 10(10):847-50.

-Ten versus 28 days of cimetidine treatment for duodenal ulcer in Iran. Evidence for the need for risk-oriented individual treatment of ulcer patients.
Malekzadeh R, Ayattallahi MT, Massarrat S.
Hepatogastroenterology. 1991 Aug; 38(4):295-8.